BridgeMD
New treatment option for Solid Tumors
Official title Protecting the Kidney's Proximal Tubules From Platinum-Based Chemotherapy Toxicity
ClinicalTrials.gov ID: NCT07018622
What this study is testing
What is Dapagliflozin 10 MG Oral Tablet?
Dapagliflozin 10 MG Oral Tablet is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for solid tumors.
Also referred to as Forxiga, AZD2281.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Patients with cancer who receive platinum-based chemotherapy are at increased risk of kidney injury caused by these drugs. This form of toxicity can lead to treatment delays, dose reductions, or permanent discontinuation of chemotherapy, all of which can negatively impact cancer outcomes and increase patient morbidity.
- Phase 2: a mid-size study of how well it works
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Signed informed consent form
- Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin)
- Expected survival \> 4 months
- ECOG performance status 0-2
You likely can't join if
- History of nephrectomy
- History of kidney transplant
- Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate)
- Type 1 diabetes mellitus
- Poorly controlled type 2 diabetes (HbA1c \> 8% or fasting glucose \> 200 mg/dL in the past month)
- Active glomerulopathy
See the full eligibility criteria
- Signed informed consent form
- Diagnosis of a solid tumor requiring a platinum-based chemotherapy regimen (cisplatin or carboplatin)
- Expected survival \> 4 months
- ECOG performance status 0-2
- History of nephrectomy
- History of kidney transplant
- Concurrent use of known nephrotoxic drugs (e.g., aminoglycosides, amphotericin B, cyclophosphamide, ifosfamide, methotrexate)
- Type 1 diabetes mellitus
- Poorly controlled type 2 diabetes (HbA1c \> 8% or fasting glucose \> 200 mg/dL in the past month)
- Active glomerulopathy
- Prior use of SGLT2 inhibitors or current indication for their use
- eGFR \< 20 ml/min/1.73 m²
- Active urinary tract infection
- Unresolved obstructive uropathy
- Participation in another clinical trial
- History of recurrent genitourinary infections
The study team makes the final eligibility decision.
Where it's taking place
- México, Tlalpan, Mexico
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include México, Tlalpan, Mexico. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.